


SUPPLEMENTARY APPENDIX


Supplemental Figure 1. COU-AA-302 Primary and Secondary End Points

Measure Key Landmarks of Disease Progression in mCRPC



ECOG PS denotes Eastern Cooperative Oncology Group performance status;
mCRPC, metastatic castrate-resistant prostate cancer; OS, overall survival; rPFS,
radiographic progression-free survival.

Supplemental Figure 2. CONSORT Diagram



**Supplemental Table 1. Radiographic Progression-free Survival Definition per
Modified Response Evaluation Criteria in Solid Tumors (RECIST), or
Progression by Bone Scan as Adapted by Prostate Cancer Working Group
Criteria 2 (PCWG2)**

rPFS Definition

- Progressive disease by bone scan: adapted from Consensus Criteria²
 - Blinded central radiologist review
 - <12 weeks after randomization
 - ≥2 new bone lesions plus 2 additional at confirmation (“2+2”)
 - ≥12 weeks after randomization
 - ≥2 new bone lesions with subsequent confirmation
 - Progressive disease (soft tissue lesions) by computed tomography or magnetic resonance imaging by modified RECIST criteria
 - Death from any cause
-

Supplemental Table 2. Statistical Plan*

Overall Assumption	rPFS	OS*
α	0.01	0.04
Power	91%	85%
Hazard ratio	0.67	0.80
Expected events	378	773

*Protocol with detailed statistical plan provided in Supplementary Material

rPFS denotes radiographic-free survival, OS overall survival.

Supplemental Table 3. Analysis Plan for Overall Survival.

Analyses				
	Interim 1*	Interim 2	Interim 3	Final
	(~15% of Total Events)	(40% of Total Events)	(55% of Total Events)	
Projected Observed	116	311	425	773
Overall Survival				
Events				
Efficacy Boundary	0.336	0.672	0.751	0.861
(HR) [†]				
Cumulative Stop Prob.	0.0001	0.0005	0.0034	0.0400
Under (H_0) [†]				

*At the time of final rPFS analysis by independent review.

[†]Pre-specified HR and P values for significance of the overall survival end point are a function of the number of events that preceded the analysis.

HR denotes hazard ratio, H_0 No improvement.

Supplemental Table 4. Selected Subsequent Therapy for Prostate Cancer

	Abiraterone (N = 546)	Prednisone (N = 542)
	n (%)	n (%)
Number of patients with selected subsequent therapy for prostate cancer	242 (44)	327 (60)
Docetaxel	207 (38)	287 (53)
Cabazitaxel	45 (8)	52 (10)
Ketoconazole	39 (7)	63 (12)
Sipuleucel-T	27 (5)	24 (4)
Abiraterone acetate	26 (5)	54 (10)

*The following additional investigators, listed in alphabetical order, participated in the COU-AA-302 study: **Australia** – A. Boyce (Lismore, NSW), A. Costello (Parkville, VIC), I. Davis (Heidelberg, VIC), V. Ganju (Frankston, VIC), L. Horvath (Camperdown, NSW), R. Lynch (Geelong, VIC), G. Marx (Wahroonga, NSW), F. Parnis (Kurralta Park, SA), J. Shapiro (Malvern, VIC), N. Singhal (Adelaide), M. Slancar (Southport), G. Van Hazel (Perth, WA), S. Wong (Footscray, VIC) S. D. Yip (Garran, ACT); **Belgium** – P. Carpentier (Aalst), D. Luyten (Hasselt), S. Rottey (Gent), F. Van Aelst (Roeselare); **Canada** – T. Cheng (Calgary, AB), J. Chin (London, ON), S. Ellard (Kelowna, BC), Y. Fradet (Quebec, PQ), M. Gleave (Vancouver, BC), A. Joshua (Toronto, ON), L. Klotz (Toronto, ON), H. Martins (Victoria, BC), S. North (Edmonton, AB), S. Pautler (London, ON); **France** – S. Abdel-Hamid (Montpellier), M. Colombel (Lyon, Cedex), A. Fléchon (Lyon), O. Haillot (Tours, Cedex), F. Joly (Caen, Cedex), S. Oudard (Paris), F. Priou (La Roche sur Yon), E. Raymond (Clichy); **Germany** – P. Albers (Düsseldorf), M. Boegemann (Münster), J. Gleissner (Wuppertal), J. Gschwend (Meunchen), P. Hammerer (Braunschweig), A. Heidenreich (Aachen), M. Kuczyk (Hannover), K. Miller (Berlin), R. Oetzel (Leipzig), J. Roigas (Berlin), T. Steuber (Hamburg), M. Stöckle (Homberg/Saar), M. Wirth (Dresden); **Greece** – C. Papandreou (Larisa, GRC); **Italy** – S. Bracarda (Arezzo), T. Marcello (San Luigi, AOU), C. Sternberg (Rome); **Netherlands** – C. Bangma (Rotterdam), T. de Reijke (Amsterdam); **Spain** – J. Arranz Arija (Madrid), J. Bellmunt (Barcelona), R. Lopez (Santiago de Compostela), M. Lopez-Brea (Santander); **Sweden** - A. Bjartell (Malmo), J. Damber (Gothenburg), M. Haggman (Uppsala), M. Hellstrom (Stockholm), M. Seke (Växjö); **United Kingdom** – J. Brown (Leeds, West Yorkshire), S. Chowdhury (London, Greater London), T. Elliott (Manchester, Lancashire), S. Harland (London), H. Innes (Bebington, Wirral),

N. James (Birmingham, West Midlands), R. Jones (Glasgow, Scotland), D. Mazhar (Cambridge, Cambridgeshire), E. Paez (Newcastle Upon Tyne, Tyne and Wear), A. Protheroe (Oxford, Oxfordshire), J. Staffurth (Cardiff, Wales, South Glamorgan);

United States – F. Ahmann (Tucson, AZ), G. Andriole (St. Louis, MO), E. Arrowsmith (Chattanooga, TN), V. Assikis (Atlanta, GA), A. Baron (San Francisco, CA), W. Berry (Raleigh, NC), G. Bubley (Boston, MA), J. Carney (Honolulu, HI), L. Chu (Ft. Myers, FL), T. Cosgriff (Metairie, LA), S. Denmeade (Baltimore, MD), H. Deshpande (New Haven, CT), D. Duchene (Kansas City, KS), A. Ferrari (New York, NY), E. Frenkel (Dallas, TX), N. Gabrail (Canton, OH), J. Garcia (Cleveland, OH), D. Georgel (Durham, NC), L. Gomella (Philadelphia, PA), O. Goodman (Las Vegas, NV), I. Gore (Birmingham, AL), J. Gullo (Syracuse, NY), J. Hainsworth (Nashville, TN), O. Hamid (Los Angeles, CA), T. Hutson (Dallas, TX), D. King (St. Louis Park, MN), H. Koh (Bellflower, CA), A. Koletsky (Boca Raton, FL), F. Kudrik (Columbia, SC), P. Lara (Sacramento, CA), R. Lyons (San Antonio, TX), J. Maranchie (Pittsburgh, PA), M. Modiano (Tucson, AZ), J. Nieva (Billings, MT), L. Nordquist (Omaha, NE), J. Pinski (Los Angeles, CA), B. Polesz (Syracuse, NY), J. Polikoff (San Diego, CA), D. Quinn (Los Angeles, CA), C. Redfern (San Diego, CA), S. Riggs (Virginia Beach, VA), C. Ryan (Portland, OR), M. Saleh (Atlanta, GA), A. Sartor (New Orleans, LA), M. Scholz (Marina Del Rey, CA), N. Shore (Myrtle Beach, SC), S. Srinivas (Stanford, CA), M. Taplin (Boston, MA), U. Vaishampaya (Detroit, MI), J. Vieweg (Gainesville, FL), M. Vira (New Hyde Park, NY), N. Vogelzang (Las Vegas, NV), G. Wilding (Madison, WI), Y. Wong (Philadelphia, PA).